However, special consideration must be given to elderly patients and those with advanced tubulointerstitial damage (≥30% atrophy), who require careful dose individualization guided by serial PLA2R antibody monitoring and repeat histopathological assessments to balance efficacy against infection risks. Here, PLA2R1 is linked to infection.